Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
|
|
- Melissa Phelps
- 6 years ago
- Views:
Transcription
1 Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP
2 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of reactive T-cells infiltrate,.
3 HRS cells interaction with microenvironment Aldinucci et al. J Pathol 2010 Jul;221(3):248-63
4 Hodgkin lymphoma: treatment modalities
5 Hodgkin lymphoma: treatment modalities
6 Hodgkin Lymphoma: Depletion of malignant cells Chemotherapy and Radiotherapy approach Autologous stem-cell transplant Antibody-drug conjugate: Brentuximab vedotin ABVD BEACOPP
7 Hodgkin Lymphoma: Depletion of malignant cells Chemotherapy and Radiotherapy approach Autologous stem-cell transplant Antibody-drug conjugate: Brentuximab vedotin BEACOPP ABVD
8 Hodgkin Lymphoma - treatment Early favorable Early unfavorable Advanced stages
9 Current guidelines for HL treatment Treatment setting Frontline NCCN guidelines, 2016 Treatment ABVD + IFRT Stanford V BEACOPP BEACOPP followed by ABVD + RT ABVD alone Individualized treatment may be necessary for older patients and patients with concomitant disease (2A) ESMO guidelines, 2014 Treatment ABVD or BEACOPP ± RT (I II,A) Second-line Salvage chemotherapy + ASCT Salvage chemotherapy + ASCT Third line therapy Brentuximab vedotin Allo SCT No data to support superior outcomes with any treatment; individualized therapy recommended Clinical trial may be appropriate Brentuximab vedotin Allo SCT No data to support superior outcomes with any treatment; individualized therapy recommended Clinical trial may be appropriate
10 Current guidelines for HL treatment Treatment setting Frontline NCCN guidelines, 2016 Treatment ABVD + IFRT Stanford V BEACOPP BEACOPP followed by ABVD + RT ABVD alone Individualized treatment may be necessary for older patients and patients with concomitant disease (2A) ESMO guidelines, 2014 Treatment ABVD or BEACOPP ± RT (I II,A) Second-line Radiotherapy or second-line chemotherapy ± radiotherapy followed by high-dose chemotherapy + ASCT/allo-SCT Salvage chemotherapy + ASCT BEACOPP escalated or salvage radiotherapy alone Third line therapy Brentuximab vedotin Allo SCT No data to support superior outcomes with any treatment; individualized therapy recommended Clinical trial may be appropriate Brentuximab vedotin Allo SCT No data to support superior outcomes with any treatment; individualized therapy recommended Clinical trial may be appropriate
11 Current guidelines for HL treatment Treatment setting Frontline NCCN guidelines, 2016 Treatment ABVD + IFRT Stanford V BEACOPP BEACOPP followed by ABVD + RT ABVD alone Individualized treatment may be necessary for older patients and patients with concomitant disease (2A) ESMO guidelines, 2014 Treatment ABVD or BEACOPP ± RT (I II,A) Second-line Salvage chemotherapy + ASCT Salvage chemotherapy + ASCT Third line therapy Brentuximab vedotin Allo SCT No data to support superior outcomes with any treatment; individualized therapy recommended Clinical trial may be appropriate Brentuximab vedotin Allo SCT No data to support superior outcomes with any treatment; individualized therapy recommended Clinical trial may be appropriate
12 Why a biopsy is mandatory? 34 y/o white female with fever, night sweats and a newly diagnosed advanced stage HL Pcte sexo feminino, 34 anos Stage: IVB Interin PET After C2 ABVD PET + Partial Response After C4 ABVD PET + After C6 ABVD PET + Refractory HL? After 1 month Tb treatment Bx: Tuberculosis
13 2 nd line therapy for chl relapsed refractory disease High dose chemotherapy followed ASCT Which salvage chemotherapy? How to increase CR rate before ASCT? How to improve prognosis in high risk patients after ASCT?
14 2 nd line therapy for chl relapsed refractory disease High dose chemotherapy followed ASCT Which salvage chemotherapy? How to increase CR rate before ASCT? How to improve prognosis in high risk patients?
15 2 nd line therapy for chl relapsed refractory disease High dose chemotherapy followed ASCT Salvage chemotherapy - UNIFESP 1. ICE Moskowitz et al. (2001) 2. DHAP Josting et al. (2005) 3. IGEV Santoro et al. (2007) Do not delay cycles DHAP 14, ICE 15 have shown the best 4. GDP Bartlett et al. (2007) results CR rate ICE, DHAP, IGEV, GDP %
16 Probability of OS (%) Response to salvage therapy predicts post-asct survival Survival correlates with depth of response prior to ASCT 1 n Complete response 53 Partial response 96 Resistant 46 5-year OS: 79% for patients in CR pre-asct 59% in patients with PR 17% in patients with resistant disease (p<0.0001) Complete remission is good, but not a pre-requisite! Time since transplant (years) 1. Sirohi B et al. Ann Oncol 2008;19:1312 9; 2. Majhail N et al. Biol Blood Marrow Transplant 2006;12: ;;
17 2 nd line therapy for chl relapsed refractory disease High dose chemotherapy followed ASCT Which salvage chemotherapy? How to increase CR rate before ASCT? How to improve prognosis in high risk patients? The role of Brentuximab vedotin
18 Is it possible to increase CR rate without increasing toxicity? The role of BV in savage therapy Use brentuximab vedotin (BV) with salvage chemotherapy BV-bendamustine Brentuximab vedotin 1.8 mg/kg D1 with bendamustine 90 mg/m2 on D1-2 q3w for 3 cycles ORR 92% 76 patients, 80% CR 30% used plerixafor LaCasce, et al. ASH 2016 CR rate ICE, DHAP, IGEV, GDP % Brentuximab Vedotin Plus ESHAP (BRESHAP) Garcia-Sans, et al. EBMT 2016 (poster) GELTAMO ORR 94% 39 patients, 85% CR
19 Is it possible to increase CR rate without increasing toxicity? The role of BV in savage therapy Brentuximab monotherapy 60 patients ORR 88% CR 65% Excellent stem-cell harvest Chen et al, EBMT 2016 (poster) B-ICE ASH 2017 preliminary results B-DHAP ISHL 2016 preliminary results CR 85% Hagenbeck et al, Oral ISHL 2016
20 2 nd line therapy for chl relapsed refractory disease High dose chemotherapy followed ASCT Which salvage chemotherapy? How to increase CR rate before ASCT? How to improve prognosis in high risk patients after ASCT?
21 AETHERA phase III trial of brentuximab vedotin vs placebo in relapsed or refractory HL pts at risk of relapse post ASCT Dose and schedule: Pts were randomized 1:1 to receive day cycles of brentuximab vedotin 1.8 mg/kg IV day 1 or placebo Pts who progressed on placebo could receive brentuximab vedotin HL, Hodgkin lymphoma; PFS, progression free survival; IRF, independent review facility; OS, overall survival; mos, months; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ASCT, autologous stem cell transplantation; BV, brentuximab vedotin; pts, patients ; R/R, relapsed refractory Moskowitz C et al. Lancet Oncology 2016
22 AETHERA phase III trial of brentuximab vedotin vs placebo in relapsed or refractory HL pts at risk of relapse post ASCT PFS outcome Brentuximab vedotin (n=165) Moskowitz C et al. Lancet Oncology 2016 Placebo (n=164) Median PFS NR 16 mos HR (95% CI) 0.50 (0.36, 0.70) p-value NR 2-year PFS 65% 45% Moskowitz C et al. Lancet Oncology 2016
23 AETHERA phase III trial of brentuximab vedotin vs placebo in relapsed or refractory HL pts at risk of relapse post ASCT Consolidation after ASCT with brentuximab vedotin (BV) demonstrated improved PFS in patients with HL and risk factors for relapse or disease progression (HR = 0.57, p = 0.001) PFS benefit was sustained after 3 years f/u (EHA 2016) Consistent benefit observed across subgroups Analysis of overall survival did not show a significant difference between treatment arms. Moskowitz C et al. Lancet Oncology 2016
24 3 rd line therapy for chl relapsed after ASCT
25 Current guidelines for HL treatment Treatment setting Frontline NCCN guidelines, 2016 Treatment ABVD + IFRT Stanford V BEACOPP BEACOPP followed by ABVD + RT ABVD alone Individualized treatment may be necessary for older patients and patients with concomitant disease (2A) ESMO guidelines, 2014 Treatment ABVD or BEACOPP ± RT (I II,A) Second-line Radiotherapy or second-line chemotherapy ± radiotherapy followed by high-dose chemotherapy + ASCT/allo-SCT Salvage chemotherapy + ASCT BEACOPP escalated or salvage radiotherapy alone Third line therapy Brentuximab vedotin Allo SCT Clinical trial may be appropriate Brentuximab vedotin Allo SCT Clinical trial may be appropriate
26 Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma Chen et al, Blood 2016 Single agent brentuximab vedotin can induce durable remissions 5-year overall survival rate was 41% and 70% for those who achieved CR
27 Current guidelines for HL treatment Treatment setting Frontline NCCN guidelines, 2016 Treatment ABVD + IFRT Stanford V BEACOPP BEACOPP followed by ABVD + RT ABVD alone Individualized treatment may be necessary for older patients and patients with concomitant disease (2A) ESMO guidelines, 2014 Treatment ABVD or BEACOPP ± RT (I II,A) Second-line Radiotherapy or second-line chemotherapy ± radiotherapy followed by high-dose chemotherapy + ASCT/allo-SCT Salvage chemotherapy + ASCT BEACOPP escalated or salvage radiotherapy alone Third line therapy Brentuximab vedotin Allo SCT Clinical trial may be appropriate Brentuximab vedotin Allo SCT Clinical trial may be appropriate
28 Hodgkin lymphoma: treatment modalities
29 New medications: Cancer immunotherapy 29
30 WHEN A T-LYMPHOCYTE MEETS AN ANTIGEN 1. T cells recognize antigens presented on the MHC by the TCR (SIGNAL 1) APC CD4 Lymphocyte
31 WHEN A T-LYMPHOCYTE MEETS AN ANTIGEN 1. T cells recognize antigens presented on the MHC by the TCR (SIGNAL 1) APC CD4 Lymphocyte 2. The activation or inhibition of T cells is determined by the additional ligand receptor interactions between T cells and APCs (or tumour cells) (SIGNAL 2) 1. Release of cytokines (SIGNAL 3)
32 WHEN A T-LYMPHOCYTE MEETS AN ANTIGEN 1. T cells recognize antigens presented on the MHC by the TCR (SIGNAL 1) APC CD4 Lymphocyte 2. The activation or inhibition of T cells is determined by the additional ligand receptor interactions between T cells and APCs (or tumour cells) (SIGNAL 2) 1. Release of cytokines (SIGNAL 3)
33 Hodgkin Lymphoma: Immune activation Allogeneic SCT Immune checkpoint inhibitors (inhibitory effect) Immune checkpoint activators (activation effect)
34 Activating or inhibitory receptors 34
35 Hodgkin Lymphoma: Immune activation Immune checkpoint inhibitors (inhibitory effect) Immune checkpoint activators (activation effect)
36 Immune checkpoints in HL Teach your body to fight tumor Haematologica cover July 2016
37 Inhibitory receptors 37
38 Regulatory T-cells in Hodgkin Lymphoma Regulatory T-cells surround HRS cells (Assis et al, Med Oncol, 2012) EBV increases Tregs in tumor microenvironment (Assis et al, Leukemia & Lymphoma, 2014) Increased Tregs in peripheral blood of patients with chl at diagnosis. (Silva et al, Clin Leuk, Lymph and Myel, 2015)
39 Regulatory T-cells in Hodgkin Lymphoma Regulatory T-cells downregulate anti-tumor immune response
40 CTLA-4 Inhibitors: Ipililumab mechanism of action
41 Activating or inhibitory receptors 41
42 PD-1 Inhibitors in Hodgkin Lymphoma: Pembrolizumab and nivolumab
43 PD-1 Inhibitors in Hodgkin Lymphoma: Pembrolizumab and nivolumab
44 Results of PD1 Blocking Antibodies in Relapsed HL (all pts received BV) Drug Dose/Sche dule N % ORR % CR ORR in BV treated HL 1 st Author Pembrolizumab (humanized IgG4) 10 mg/kg IV Q 2wks 15 53% 20% 53% (n=15) Moskowitz C Nivolumab (Fully human IgG4) 3 mg/kg IV Q 2wks 23 87% 17% 89% (n=18) Armand P Phase 2 trials on going
45 Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412) Stephen Ansell et al, Poster, ASH 2016 E4412 is a phase 1 study of the combination of BV and the checkpoint inhibitors ipilimumab (anti-ctla-4) (IPI) and nivolumab (NIVO) 23 patients have been treated with BV + IPI (first cohort) BV + IPI was well tolerated Overall response BV + IPI was 87% with a CR rate of 62% Optimization of this combination strategy is planned with ongoing accrual to cohorts receiving BV + NIVO and BV + IPI + NIVO. 45
46 PD1 Blocking Antibodies: potential serious side effects
47 PD1 Blocking Antibodies: potential serious side effects Fulminant type 1 diabetes mellitus with Nivolumab J Diabetes, 2016 Fatal GVHD following Pembrolizumab Bone Marrow Transplant AIHA after nivolumab treatment Oncotarget, 2016 Vitiligo induced by nivolumab Cancer reviews, 2016 Myasthenia gravis induced by nivolumab JAMA Oncol, 2016
48 Single agent activity of novel agents in relapsed chl: update CR PR 25 0
49 Current and Future Treatment Paradigms of Hodgkin Lymphoma Strategy A Strategy B PD1/PDL1 an bodies Chemo therapy Brentuximab Vedo nn PI3Ki/ mtori Chemo therapy Brentuximab Vedo nn + PD1/PDL1 an body PI3Ki/ mtori HDACi HDACi Courtesy: Prof. Anas Younes
50 Obrigado
51 Current and Future Treatment Paradigms of Hodgkin Lymphoma ABVD ABVD 2020? No response/relapse No response/relapse No response/relapse Platinum-based salvage Platinum-based salvage? And/or And/or And/or Gemcitabine-based salvage Gemcitabine-based salvage? ASCT ASCT? No response/relapse No response/relapse No response/relapse? Brentuximab AlloSCT?
Relapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More informationHodgkin Lymphoma New Combo-Steps
New Drugs In Hematology Hodgkin Lymphoma New Combo-Steps Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:55-3:10 p.m Combinations with Immune Checkpoint
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationAdvances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
Wang et al. Journal of Hematology & Oncology (2018) 11:57 https://doi.org/10.1186/s13045-018-0601-9 REVIEW Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma Yucai Wang 1, Grzegorz
More informationTreatment Approaches in Relapsed/Refractory HL. Brentuximab Vedo=n. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center
Treatment Approaches in Relapsed/Refractory HL Brentuximab Vedo=n Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Thursday March 15, 2018: 10:15-10:30 am 1992 (Cell): Durkop
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationWelcome and Introductions
Update on Hodgkin Lymphoma Matthew J Matasar, MD, MS Physician, Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York, NY April 1, 2016
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationBrentuximab Vedotin in Lymphomas
New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000
More informationBrentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase
Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationLinfoma di Hodgkin Tra/amento dei pazien4 ricadu4
Linfoma di Hodgkin Tra/amento dei pazien4 ricadu4 Simonetta Viviani SC Ematologia e Trapianto di Midollo osseo Dichiarazione Relatore: SimoneGa Viviani Posizione di dipendente in aziende con interessi
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Robert Chen, MD Associate Professor of Medicine Co-Leader of Lymphoma Disease Team Associate Director of Toni Stephenson Lymphoma Center City of Hope National Medical
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationHodgkin Lymphoma Nivolumab
New Drugs In Hematology Hodgkin Lymphoma Nivolumab Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:10-2:25 p.m immunotherapy modalities CAR T Cells
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationHodgkin Lymphoma. Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois
Hodgkin Lymphoma Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois Hodgkin Lymphoma Successes and Challenges The success 80 % of patients achieve
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Assess the efficacy and safety of brentuximab vedotin in investigational settings, such as in combination with AVD for patients with newly diagnosed HL, as consolidation
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationDoes BV as part of salvage impact outcome?
Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College
More informationNew Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic
New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic Disclosures for Stephen Ansell, MD, PhD In compliance with ACCME policy, Mayo Clinic
More informationCheckpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD
Checkpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD Disclosures for Rob Laister Research Support Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationRelapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma
Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing
More informationThe Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma
The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Institut Catala d Oncologia Hospital Duran I Reynals Barcelona, Spain 10 th Educational
More informationEmerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma
Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma Presented as a Live Webinar Thursday, October 26, 2017 1:00 2:00 p.m. ET On-demand Activity Live webinar recorded and archived to be
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationThe Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma
The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Hospital Universitari Quirón Dexeus Barcelona, Spain 9 th Educational Course on Lymphomas
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationLead team presentation Nivolumab for relapsed or refractory classical Hodgkin lymphoma (STA)
Lead team presentation Nivolumab for relapsed or refractory classical Hodgkin lymphoma (STA) 1 st Appraisal Committee meeting Background and Clinical Effectiveness Committee C Lead team: Nigel Langford,
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationNK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationbrentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd
brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationAGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM
AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationPD-1/PD-L1 inhibitors in hematological malignancies, with focus on Lymphoid Malignancies
PD-1/PD-L1 inhibitors in hematological malignancies, with focus on Lymphoid Malignancies Professor Lim Soon Thye Head, Division of Medical Oncology National Cancer Centre Singapore Head, Singhealth Duke-NUS
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationChanging the landscape of treatment in Peripheral T-cell Lymphoma
Changing the landscape of treatment in Peripheral T-cell Lymphoma Luis Fayad Associate Professor MD Anderson Cancer Center Department of Lymphoma and Myeloma 1 6 What is peripheral 2008 WHO CLASSIFICATION
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 27 th Prioritization 2 nd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationWelcome & Introductions
Living with Hodgkin Lymphoma Welcome & Introductions Dr. Lamar s slides are available for download at www.lls.org/programs, under the program listing. 1 Living with Hodgkin Lymphoma Living with Hodgkin
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationNovel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma
HODGKIN LYMPHOMA: TREATMENT TODAY AND THE CHALLENGE FOR TOMORROW Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma Craig Moskowitz Memorial Sloan-Kettering
More informationImmunotherapy in haematological malignancies. Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona
Immunotherapy in haematological malignancies Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Roche Celgene Mundipharma Janssen Gilead Bayer Millenium What
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationNovel Therapeutic Targets for Hodgkin Lymphoma
Hodgkin Lymphoma:...Therapeutic Biology Novel Therapeutic Targets for Hodgkin Lymphoma Antonello Pinto Hematology-Oncology and Stem Cell Transplantation Unit Department of Hematology National Cancer Institute,
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Pembrolizumab (Keytruda) for Classical Hodgkin Lymphoma January 5, 2018
pan-canadian Oncology Drug Review Final Clinical Guidance Report Pembrolizumab (Keytruda) for Classical Hodgkin Lymphoma January 5, 2018 DISCLAIMER Not a Substitute for Professional Advice This report
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab (Adcetris) for Hodgkin Lymphoma - Resubmission February 21, 2018
pan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab (Adcetris) for Hodgkin Lymphoma - Resubmission February 21, 2018 DISCLAIMER Not a Substitute for Professional Advice This report
More informationBENDAMUSTINE IN HODGKIN LYMPHOMA
CONVEGNO REGIONALE SIE DELEGAZIONE REGIONALE EMILIA ROMAGNA ATTUALITA IN EMATOLOGIA BOLOGNA 06.03.2015 BENDAMUSTINE IN HODGKIN LYMPHOMA Dott.ssa Cinzia Pellegrini Istituto di Ematologia e Oncologia Medica
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationPresented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9 12, 2017; Atlanta, GA, USA
65 Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 25 Study Jonathon B. Cohen, 1 Andreas
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY
ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE
More informationPeripheral T-cell lymphomas (PTCL) Specified and Unspecified. Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles
Peripheral T-cell lymphomas (PTCL) Specified and Unspecified Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles BHS seminar 12, 07 March 2015 Peripheral T-cell lymphomas (PTCL) Specified and
More informationLINFOMA DI HODGKIN: RUOLO DEI CHECKPOINT INHIBITORS Armando Santoro
LINFOMA DI HODGKIN: RUOLO DEI CHECKPOINT INHIBITORS Armando Santoro CANCER IMMUNOTHERAPY TODAY TUMORS RESPONSIVE TO ANTI-PD1 OR ANTI-PD-L1 THERAPY! MELANOMA! RCC! NSCLC! UROTHELIAL CANCER! HEAD AND NECK
More informationBleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath
Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath Rachel Bubik, PharmD, BCPS PGY-2 Hematology/Oncology Pharmacy Resident January 8 th, 2019 2017 MFMER slide-1 Objectives 1. Explain
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More information